14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
CELUW vs CELU: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
CELU Wins Head-to-Head Institutional Verdict (5–0 across 6 Pillars · 7–0 Matrix Metrics)
CELU Overall Winner
6-Pillar Tally: CELUW 0 – 5 CELU (1 Tie)
Matrix Metrics: CELUW 0 – 7 CELU
As of Nov 20, 2026, Celularity Inc. (CELU) is the stronger overall head-to-head candidate over CELUW (CELUW) in the Tradestie Institutional Equity Comparison Engine, winning 7–0 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CELUW carries a Unified Composite Score of 41.3/100 (SELL) at $0.00 (N/M Forward P/E, N/A operating margin), whereas CELU carries 42.9/100 (HOLD) at $0.46 (N/M Forward P/E, -254.0% operating margin).
Technical & Structure Timing Caution: CELUW is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 42.5); meanwhile CELU is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 26.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CELUW vs CELU. Trailing 12-month operating profitability (CELUW N/A vs CELU -254.0%) and valuation multiples (CELUW N/M vs CELU N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
CELU Moat ProfileCyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $15.2M market capitalization and -254.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ CELUW vs CELU Key Questions & Quantitative Answers
As of Nov 20, 2026, Celularity Inc. (CELU) is the stronger overall head-to-head candidate over CELUW (CELUW) in the Tradestie Institutional Equity Comparison Engine, winning 7–0 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CELUW carries a Unified Composite Score of 41.3/100 (SELL) at $0.00 (N/M Forward P/E, N/A operating margin), whereas CELU carries 42.9/100 (HOLD) at $0.46 (N/M Forward P/E, -254.0% operating margin). Technical & Structure Timing Caution: CELUW is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 42.5); meanwhile CELU is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 26.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
CELU leads the Growth & Scale pillar: CELUW posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with CELU at -5.3% YoY revenue growth and -61.3% YoY earnings growth on $19M TTM revenue (19.2% gross margin, -254.0% operating margin). On trailing 12-month operating scale, CELUW generates N/A in USD-normalized revenue versus $19M for CELU. In operating R&D and SG&A reinvestment, CELUW deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CELU.
CELU screens cheaper on headline valuation multiples. CELUW trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas CELU trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 2.7x EV/Revenue (-47.8% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CELUW (N/A ROE) versus CELU (-6367.2% ROE) capital efficiency.
In options market volatility and institutional positioning, CELUW carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.52β · 2163% Vol realized risk). By comparison, CELU carries 116.6% implied volatility (50th %ile, Balanced (25th–60th %ile)), a 3.60x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (2.01β · 135% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.